Revenue during the quarter surged 32.70 percent to $124.68 million from $93.96 million in the previous year period. Gross margin for the quarter expanded 16 basis points over the previous year period to 84.55 percent. Total expenses were 76.75 percent of quarterly revenues, down from 78.91 percent for the same period last year. This has led to an improvement of 217 basis points in operating margin to 23.25 percent.

Operating income for the quarter was $28.99 million, compared with $19.81 million in the previous year period.

"Abiomed remains one of the fastest growing GAAP profitable companies and fiscal 2017 was another successful year as we achieved our corporate goals with two FDA approvals, approval in Japan, and dedicated DRGs from the Centers for Medicare and Medicaid Services (CMS)," said Michael R. Minogue, chairman, president and chief executive officer, Abiomed. "We want to thank our shareholders for their support and all of our employees and customers for their hard work and dedication to patients and our mission of heart recovery."

For fiscal year 2018, Abiomed, Inc. projects revenue to be in the range of $555 million to $575 million for financial year 2018. The company projects operating income to grow in the range of 22 percent to 24 percent.